A Phase 1B Study of CHS-114 With Toripalimab and Other Treatments for Advanced or Metastatic Solid Tumors

What this Trial Is About

Researchers are evaluating the safety and preliminary effectiveness of a drug called CHS-114 combined with toripalimab and possibly other standard treatments in adults with advanced or metastatic solid tumors. This Phase 1B study focuses on participants with specific types of solid tumors, including gastric, esophageal, and colorectal cancers, to understand how these treatments work together in this serious condition. Participants receive CHS-114 through an intravenous infusion along with toripalimab every three weeks. Some groups may also receive additional drugs like 5 fluorouracil and cisplatin. The study includes several treatment groups with different doses and combinations to compare effects and safety. Treatment and monitoring may continue for up to about 2.25 years. During the study, participants undergo regular assessments to monitor side effects, tumor response, and drug levels in the blood. Researchers track treatment-emergent adverse events for up to 90 days after the last dose, and tumor response and progression are evaluated using standard criteria. Participants provide tumor tissue samples and undergo safety monitoring throughout the trial, which may last until early 2028.

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors